In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vanda Pharmaceuticals nets $55.4mm from IPO

Executive Summary

Vanda Pharmaceuticals, a start-up biotech developing small-molecule psychiatric drugs, netted $55.4mm from its IPO of 5.96mm shares (including the overallotment) at $10 apiece. In December 2005 the company filed for a $75mm IPO, and later in March for a $92.5mm one.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies